Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193958 · ClinicalTrials.gov registry record · Phase 1
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02193958 is a Phase 1 study that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 55 participants.
The verdict
NCT02193958, a Phase 1 study, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. A total of 20 subjects with MDS/CMML treated at the RP2D are planned, including MDS/CMML subjects treated at the RP2D in Phase 1.
Interventions
- DRUG FF-10501-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193958
The ClinicalTrials.gov registry entry for NCT02193958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fujifilm Pharmaceuticals U.S.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FF-10501-01 is the first listed.
NCT02193958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193958 about?
NCT02193958 is a clinical study titled "Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies". A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. A total of 20 subjects with MDS/CMML treated at the RP2D are planned, ...
What is the current status of trial NCT02193958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2014-07. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT02193958?
The interventions under investigation include: FF-10501-01 (DRUG).
Who is sponsoring clinical trial NCT02193958?
This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.